Vectus Biosystems Limited (ASX: VBS) - Share Price
- Current share price for VBS : $0.125
Vectus Biosystems Limited (VBS), an ASX-listed company, is developing treatments for fibrosis, including for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Funds from the IPO and from two subsequent fundraisings were used predominantly to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure.
VBS General Information +
| ASX Code | VBS |
| Website | http://www.vectusbiosystems.com.au |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 7 |
| VBS Share Price | $0.125 |
| Day High | $0.125 |
| Day Low | $0.100 |
| Last Close | $0.125 |
| VBS Share Price Movement | - ( No change ) |
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Vectus Biosystems Limited (VBS) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Vectus Biosystems Limited (VBS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Vectus Biosystems Limited (VBS) price-sensitive announcements
VBS - Placement of Shares
Vectus Biosystems Limited announced a $0.8 million placement to accelerate their VB0004 cl
Vectus Biosystems Limited (VBS)
22 May 2026 | 3:18 PM
22 May 2026 | 3:18 PM
VBS - Appointment of Dr Tara Speranza as CEO & CTO
Vectus Biosystems Limited announced the appointment of Dr. Tara Speranza as Chief Executiv
Vectus Biosystems Limited (VBS)
7 May 2026 | 5:09 PM
7 May 2026 | 5:09 PM
VBS - Quarterly Activities & Appendix 4C Cash Flow Reports
Vectus Biosystems Limited, an Australian company, is developing treatments for fibrosis wi
Vectus Biosystems Limited (VBS)
30 Apr 2026 | 3:10 PM
30 Apr 2026 | 3:10 PM
VBS - VB4-P5 Renal Compound Transaction Settled
Vectus Biosystems Limited announced the settlement of its transaction involving the VB4-P5
Vectus Biosystems Limited (VBS)
14 Apr 2026 | 8:12 AM
14 Apr 2026 | 8:12 AM
Vectus Biosystems Limited (VBS) Recent ASX Announcements
VBS Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$1.78 | -$3.30 | -23.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$2.34 | -$4.40 | -38.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$3.45 | -$7.20 | -39.90% | 0.00 | 0.00 | 0.00% | 0.0% |
VBS Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $56,344M | 0.1108 | -0.1296 | 0.0166 | 12.6157 | 14.4937 | 14.2573 | 3.79% | 3.06% | 3.19% |
| Clinuvel Pharmaceuticals Limited (CUV) | $507M | 0.0287 | -0.0028 | 0.1257 | 13.9972 | 14.0363 | 12.4690 | 0.50% | 0.70% | 1.53% |
| Mesoblast Limited (MSB) | $2,693M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,321M | -1.3893 | 0.0000 | -0.1304 | 0.0000 | 291.9926 | 335.7602 | 0.00% | 0.00% | 0.00% |
| Vectus Biosystems Limited (VBS) | $8M | -0.2392 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
VBS Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | -26.00 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.66 |
| Sector | 0.42 | 26.20 | 2.41 | 2.34 |
VBS Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Maurie Stang | Non-Executive Deputy Chairman, Non-Executive Director | 12 Dec 2005 |
| Ms Linda Ann Walters | Non-Executive Director | 20 Dec 2024 |
| Dr Ronald Cecil Shnier | Non-Executive Director, Non-Executive Chairman | 2 Sep 2015 |
Vectus Biosystems Limited (VBS) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 28 Dec 2022 | STANG, Maurie | Issued | Indirect Shares | 12,500 | $0.800 | $10,000.000 |
| 28 Dec 2022 | SHNIER, Ronald | Issued | Indirect Shares | 37,500 | $0.800 | $30,000.000 |
| 28 Dec 2022 | POND, Susan | Issued | Indirect Shares | 18,750 | $0.800 | $15,000.000 |
See all changes in directors' interest & trades for Vectus Biosystems Limited (VBS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
VBS Management
| Name | Position |
|---|---|
| Tara Speranza | Chief Executive Officer,Chief Technology Officer |
| Robert John Waring | Company Secretary |
VBS Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Vectus Biosystems Limited (VBS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 5,178,668 (9.72%) | Kefford Holdings Pty Ltd |
| 4,858,952 (9.11%) | Maurie Stang |
| 4,483,896 (8.41%) | Regal Funds Management Pty Ltd |
| 3,278,500 (6.15%) | Karen Duggan |
VBS Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 28 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
